Clinical trials: Liver Diseases, Alcoholic
Surgery, Obesity
A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients
The aim of the study is to demonstrate the superiority of bariatric surgery on the disappearance of NASH without worsening of fibrosis in comparison to medical standard treatment in obese patients (35 kg/m² > BMI ≥ 30 kg/m²) with…
- Conditions
- Surgery, Obesity, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
- Trial name
- NASHSURG (NCT03472157)
- Testing
- Lifestyle therapy, Bariatric surgery
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Lille
Fatty Liver, Nonalcoholic
The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver
L-carnitine is an amino acid that is naturally produced in the liver and kidneys, it is involved in transporting fatty acids across the mitochondrial membrane, it could be an important component in treating a fatty liver disease.
- Trial name
- NCT03319199
- Testing
- "SLIM WATER"
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Rawi Hazzan
Rheumatoid Arthritis, Non-Alcoholic Steatohepatitis
A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.
- Trial name
- NCT05053165
- Testing
- LB-P6, LB-P8
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- LISCure Biosciences
Obesity, Morbid, Bariatric Surgery Candidate
Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery
Morbid obesity leads to non-alcoholic fatty liver disease (NAFLD), and not all NAFLD cases benefit from weight loss e.g. after bariatric surgery.
- Conditions
- Obesity, Morbid, Bariatric Surgery Candidate, NAFLD, Microbiome
- Trial name
- NCT03391401
- Testing
- Bariatric surgery
- Where
- 2 sites in Germany
- Volunteers
- 204 people
- Sponsor
- St. Franziskus Hospital
NAFLD, Diabetes Mellitus, Type 2
Liver Fat as a Dietary Target for Treating Cardiometabolic Disorders in Prediabetes and Type 2 Diabetes
The overall aim of this study is to investigate the long-term impact of a customized diet aimed at reducing liver fat specifically and a healthy Nordic diet on ectopic fat (liver, pancreatic and visceral) and cardiometabolic risk…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, PreDiabetes
- Trial name
- NAFLDiet (NCT04527965)
- Testing
- Customized diet to reduce liver fat, Healthy Nordic diet, Control
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Non-alcoholic Fatty Liver Disease (NAFLD)
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been steadily increasing, with 10-20% of affected individuals progressing to non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT06913699
- Testing
- Ultrasonund-guided percutaneous liver biopsy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai East Hospital
Non-alcoholic Steatohepatitis, Hepatic Impairment
A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with…
- Conditions
- Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
- Trial name
- NCT05835180
- Testing
- TVB-2640 - 50 mg
- Where
- 3 sites in United States, Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sagimet Biosciences Inc.
Non-alcoholic Fatty Liver Disease, Fatty Liver
Study of Fish Oil to Reduce ALT Levels in Adolescents
This trial will provide preliminary data to test the hypothesis that a six-month treatment period with fish oil for overweight adolescent with mild to moderate persistent elevation of ALT levels and presence of hepatic steatosis…
- Trial name
- NCT00694746
- Testing
- Omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston University
Liver Cirrhosis, Alcoholic
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
In this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis.
- Trial name
- NCT06057870
- Testing
- Application on Apple watch
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Nonalcoholic Fatty Liver, Weight Loss
Study on GS300 on NAFLD
To determine the efficacy of GS300 when administered for 24 weeks in patients with Nonalcoholic Fatty Liver Disease (NAFLD).
- Trial name
- REVERT (NCT04887766)
- Testing
- GS300
- Volunteers
- 250 people
- Sponsor
- Gelesis, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
The objective is to evaluate the efficacy and safety of once-daily oral doses of 10 mg elobixibat in combination with 9g cholestyramine powder (cholestyramine 4g) in patients with nonalcoholic fatty liver disease (NAFLD) or…
- Trial name
- NCT04235205
- Testing
- Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
- Where
- Japan
- Volunteers
- 102 people
- Sponsor
- Yokohama City University
Cardiovascular Diseases
Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers
The risk of cardiovascular disease is determined by the complex interplay between an individual's genetic make-up, lifestyle, and the environment.
- Trial name
- CADBIO (NCT03038750)
- Testing
- Eligibility and lifestyle restrictions check., Medical history, demographic and lifestyle factors, Anthropometric measurements: height, weight, and body fat
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes
Weight Gain After Smoking Cessation and NAFLD
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common chronic liver disease. Considering that there are no approved pharmacological treatments, lifestyle modification is necessary and challenging to reduce…
- Trial name
- NCT05550688
- Where
- China
- Volunteers
- 12,941 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Fatty Liver, Nonalcoholic
Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease
Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
- Trial name
- NCT06491342
- Testing
- Probiotic
- Where
- 2 sites in Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin…
- Conditions
- Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT04976283
- Testing
- Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin
- Where
- Pakistan
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Portal Hypertension
- Trial name
- NCT03439189
- Testing
- Methacetin Breath Test, Emricasan
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Meridian Bioscience, Inc.
Non-Alcoholic Fatty Liver Disease
Effectiveness and Adherence of Modified Alternate-day Calorie Restriction (MACR) in Non-Alcoholic Fatty Liver Disease
There is no effective therapy for non-alcoholic fatty liver disease (NAFLD), although intensive calorie restriction is typically recommended but dietary adherence is an issue.
- Trial name
- NCT03791203
- Testing
- Calorie restriction (MACR)
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Non-Alcoholic Fatty Liver Disease
The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study
Non-alcoholic fatty liver disease (NAFLD) is a liver disease, caused by storage of fat in the liver. The most-important risk-factors are being overweight, and disorders in sugar and cholesterol handling of the body.
- Trial name
- NLA2 (NCT05712603)
- Testing
- FIB4-score, Vibration controlled transient elastography, Enhanced Liver Fibrosis test
- Where
- 3 sites in Netherlands
- Volunteers
- 655 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Non-alcoholic Fatty Liver Disease
Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
The study is designed to assess the safety and efficacy of different doses and dosing regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in prevention of liver disease progression in patients with…
- Trial name
- NCT02930161
- Testing
- Runihol
- Where
- 3 sites in Russia
- Volunteers
- 35 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
NASH - Nonalcoholic Steatohepatitis
Multiple Ascending Dose Study of HU6 in High BMI Volunteers
This is a 14-day multiple ascending dose trial in high BMI volunteers in up to 4 cohorts of 10 high BMI volunteers each consisting of 8 receiving HU6 and 2 receiving placebo.
- Trial name
- NCT04709913
- Testing
- HU6
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.